The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes... Adv Ther (2017) 34:2612–2624 DOI 10.1007/s12325-017-0643-3 ORIGINAL RESEARCH The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies . . . Tomohiro Kusawake Donna Kowalski Akitsugu Takada . . . . Kota Kato Masataka Katashima James J. Keirns Michaelene Lewand . . Kenneth C. Lasseter Thomas C. Marbury Richard A. Preston Received: September 25, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication hepatic impairment and mild, moderate, and ABSTRACT severe renal impairment. Results: In the hepatic impairment study, the Introduction: Amenamevir (ASP2151) is a pharmacokinetic profile of amenamevir in par- nonnucleoside human herpesvirus helicase-pri- ticipants with moderate hepatic impairment mase inhibitor that was approved in Japan for was generally similar to that of participants the treatment of herpes zoster (shingles) in with normal hepatic function. In the renal 2017. This article reports the results of two impairment study, the area under the ame- clinical trials that investigated the effects of namevir concentration versus time curve from renal and hepatic impairment on the pharma- the time of dosing up to the time of the last cokinetics of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies

Loading next page...
 
/lp/springer_journal/the-influence-of-hepatic-and-renal-impairment-on-the-pharmacokinetics-YZpRLkes1i
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0643-3
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:2612–2624 DOI 10.1007/s12325-017-0643-3 ORIGINAL RESEARCH The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies . . . Tomohiro Kusawake Donna Kowalski Akitsugu Takada . . . . Kota Kato Masataka Katashima James J. Keirns Michaelene Lewand . . Kenneth C. Lasseter Thomas C. Marbury Richard A. Preston Received: September 25, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication hepatic impairment and mild, moderate, and ABSTRACT severe renal impairment. Results: In the hepatic impairment study, the Introduction: Amenamevir (ASP2151) is a pharmacokinetic profile of amenamevir in par- nonnucleoside human herpesvirus helicase-pri- ticipants with moderate hepatic impairment mase inhibitor that was approved in Japan for was generally similar to that of participants the treatment of herpes zoster (shingles) in with normal hepatic function. In the renal 2017. This article reports the results of two impairment study, the area under the ame- clinical trials that investigated the effects of namevir concentration versus time curve from renal and hepatic impairment on the pharma- the time of dosing up to the time of the last cokinetics of

Journal

Advances in TherapySpringer Journals

Published: Nov 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off